In today’s rapidly evolving biotechnology landscape, regulatory challenges often determine the difference between groundbreaking innovations that reach patients and those that remain trapped in development limbo. We’re excited to announce the release of our comprehensive white paper, “Navigating the Regulatory Landscape: 10 Critical Challenges for Biotech Companies,” designed to help innovators chart a successful course
Understanding and navigating the complexities of these frameworks is essential for organizations seeking efficiency, innovation, and regulatory alignment.
In the dynamic world of pharmaceuticals, ensuring patient safety is paramount. Pharmacovigilance, the science and activities relating to detecting, assessing, understanding, and preventing adverse effects or any other drug-related problem, plays a critical role in this endeavor. Mivado GlobalPerformance Inc. is a leading provider of comprehensive pharmacovigilance solutions, helping pharmaceutical companies navigate the complexities of
In the biopharmaceutical industry, cross-contamination is a significant concern, with potential impacts on product safety, efficacy, and ultimately, patient health. Cross-contamination occurs when trace amounts of one product inadvertently mix with another product, equipment, or process stream. This can lead to compromised product integrity, regulatory non-compliance, and costly recalls. From a quality assurance (QA) perspective,
N-nitrosamine impurities, a class of potentially carcinogenic substances, have become a significant concern in the pharmaceutical industry. These compounds can form during the drug manufacturing process or due to degradation.